Higher Baxter sales boost Q4 earnings; Roche's Avastin wins extended colorectal cancer use;

@FiercePharma: Results from Slovenia's Krka show why pharma's so interested in emerging markets. E. European growth push sales up 6%. More | Follow @FiercePharma

 @AlisonBFierce: After a year-long voluntary moratorium, researchers are set to resume lab-bred bird flu studies. News | Follow @AlisonBFierce

> Baxter International ($BAX) posted an increase in quarterly earnings on stronger sales, particularly in the U.S. Report

> Roche's ($RHHBY) Avastin won FDA approval for a new use in colorectal cancer patients, in combination with a different chemotherapy regimen to be used after previous Avastin-plus-chemotherapy treatment has failed. Report

> Flush with a new supply contract, South Africa's Cipla Medpro is likely to ask for a higher buyout bid from India's drugmaker Cipla. Report

> Slovenia's Krka saw full-year sales rise 6%, thanks to growth in its eastern European sales, which offset declines in its home country. Report

> India's Lupin won FDA approval for its version of Teva Pharmaceutical's ($TEVA) Plan B contraceptive. Report

> Pfizer's ($PFE) antidepressant Pristiq, a follow-up to its Effexor blockbuster, beat placebo in an 8-week phase IV study; its side effects were "consistent" with previous research, the company said. Report

Medical Device News

 @FierceMedDev: FDA slaps Class I tag on Bausch + Lomb's eye surgery recall. Report | Follow @FierceMedDev

 @DamianFierce: Some companies are passing the cost of the device tax down to customers, and hospitals are none too pleased. Story | Follow @DamianFierce

> AngioDynamics spends $15M on microwave ablation tech. Article

> Recall charges drag down Stryker's strong Q4 sales. Story

Biotech News

 @FierceBiotech: Biogen bolsters MS biz with PhIII win for longer-lasting Avonex. News | Follow @FierceBiotech

@JohnCFierce: Flu researchers are getting back to work on controversial genetically engineered viruses, whether US likes it or not. More | Follow @JohnCFierce

@RyanMFierce: Merck CEO pledges to persist with 'good' cholesterol drug program. Story | Follow @RyanMFierce

> Bristol-Myers finds silver (tax) lining after Hep C disaster. News

> Baxter snags hemophilia candidate in $185M deal with Ipsen and broke biotech. Article

Vaccines News

> U.N. excludes vaccine preservative from mercury treaty. More

> Researchers set to resume lab-bred bird flu studies. Report

> Heightened flu season turns focus on vaccine advancements. Story

> Evidence mounts for GSK flu vaccine link to narcolepsy. News

> Novartis lands EU approval of meningitis B vaccine Bexsero. Article

Pharma Manufacturing News

> AmerisourceBergen seeing shifts in drug distribution business. Item

> Drug plants popping up in Kazakhstan. Story

> Counterfeit drug seizures fell significantly in 2012. Report

> Ben Venue consent decree softened to account for drug shortages. News

And Finally... Business leaders in Davos confront the obesity conundrum. Report

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

It’s been a big year for Bristol's Opdivo-Yervoy combo in lung cancer, but with new mesothelioma data in hand, the duo isn’t done making headlines.

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.